Provectus' Lead Investigator for Phase 2 Melanoma Study to Address the Inaugural Sydney Cancer Conference 2008
Thursday July 17, 2008
Professor John F. Thompson to Speak at 11:15 am local time on Friday July 25th
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, announced today that the Lead Investigator for its Phase 2 melanoma study, Professor John F Thompson, MD, will address the inaugural Sydney Cancer Conference 2008 (SCC2008). Professor Thompson will speak at 11:15 am local time on Friday July 25th at the Eastern Avenue Auditorium and Lecture Theatre Complex at The University of Sydney, in Sydney, Australia.
Professor Richard Christopherson, Chair of the SCC2008 Organizing Committee, said the "one presentation not to be missed will be by Professor John Thompson. Professor Thompson is Director of the Sydney Melanoma Unit at The University of Sydney, and he will outline new melanoma treatments, including the ground-breaking clinical trial he is carrying out [with PV-10]."
Recently, Provectus announced that the first twenty-five percent (20 of 80) of melanoma subjects have been treated in its Phase 2 clinical trial of PV-10. Enrollment is continuing at the first two active centers, located in Brisbane and Sydney, Australia, with additional sites in Australia and the U.S expected to join the study in the coming months.
About Provectus Pharmaceuticals, Inc. (www.pvct.com)
Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry,
www.clinicaltrials.gov.
The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the
Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc. via the information provided.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Contact:
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO
866-594-5999 #30
CFO
or
Porter, LeVay & Rose, Inc.
212-564-4700
Marlon Nurse, VP - Investor Relations
or
Bill Gordon, SVP - Media Relations
212-564-4700
Source: Provectus Pharmaceuticals, Inc.
